Dayvigo is owned by Eisai Inc.
Dayvigo contains Lemborexant.
Dayvigo has a total of 2 drug patents out of which 0 drug patents have expired.
Dayvigo was authorised for market use on 07 April, 2020.
Dayvigo is available in tablet;oral dosage forms.
Dayvigo can be used as treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Drug patent challenges can be filed against Dayvigo from 2024-04-07.
The generics of Dayvigo are possible to be released after 21 October, 2035.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8268848||EISAI INC||Cyclopropane compound|| |
(8 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10188652||EISAI INC||Compositions and methods for treating insomnia|| |
(12 years from now)
|New Chemical Entity Exclusivity (NCE)||Apr 7, 2025|
Drugs and Companies using LEMBOREXANT ingredient
NCE-1 date: 2024-04-07
Market Authorisation Date: 07 April, 2020
Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic